Valneva SE
VALN6.500USD
+0.010+0.15%
Cierre 07/17, 16:00（ET）Cotizaciones retrasadas 15 min
1.06BCap. mercado
PérdidaP/E TTM
Más Datos de Valneva SE Compañía
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Información de la empresa
Símbolo de cotizaciónVALN
Nombre de la empresaValneva SE
Fecha de salida a bolsaJun 28, 2007
Fundada en1999
Director ejecutivoMr. Thomas Lingelbach
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalJun 28
Dirección6 rue Alain Bombard
CiudadSAINT-HERBLAIN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísFrance
Código postal44800
Teléfono33228073710
Sitio Webhttps://valneva.com/
Símbolo de cotizaciónVALN
Fecha de salida a bolsaJun 28, 2007
Fundada en1999
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Hanneke Schuitemaker
Dr. Hanneke Schuitemaker
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Kathrin U. Jansen, Ph.D.
Dr. Kathrin U. Jansen, Ph.D.
Director
Director
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Daniele Guyot-Caparros
Ms. Daniele Guyot-Caparros
Independent Director
Independent Director
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Hanneke Schuitemaker
Dr. Hanneke Schuitemaker
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Kathrin U. Jansen, Ph.D.
Dr. Kathrin U. Jansen, Ph.D.
Director
Director
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Desglose de ingresos
Divisa: EURActualizado: dom., 6 de jul
Divisa: EURActualizado: dom., 6 de jul
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Por negocioEUR
Nombre
Ganancia
Proporción
IXIARO
94.07M
55.47%
Third party products
33.19M
19.57%
DUKORAL
32.30M
19.05%
Chikungunya VLA1553
3.70M
2.18%
Others
1.13M
0.67%
Unallocated
704.00K
0.42%
Por regiónEUR
Nombre
Ganancia
Proporción
United States
48.59M
28.66%
Canada
32.32M
19.06%
United Kingdom
19.49M
11.49%
Germany
18.37M
10.84%
Austria
15.90M
9.37%
Other
34.91M
20.58%
Por negocio
Por región
Por negocioEUR
Nombre
Ganancia
Proporción
IXIARO
94.07M
55.47%
Third party products
33.19M
19.57%
DUKORAL
32.30M
19.05%
Chikungunya VLA1553
3.70M
2.18%
Others
1.13M
0.67%
Unallocated
704.00K
0.42%
Estadísticas de accionistas
Actualizado: mar., 13 de may
Actualizado: mar., 13 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
General American Investors Company, Inc.
0.44%
Wells Fargo Advisors
0.30%
Citadel Advisors LLC
0.03%
Ironwood Investment Management, LLC
0.03%
Other
99.20%
Accionistas
Accionistas
Proporción
General American Investors Company, Inc.
0.44%
Wells Fargo Advisors
0.30%
Citadel Advisors LLC
0.03%
Ironwood Investment Management, LLC
0.03%
Other
99.20%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
0.48%
Research Firm
0.30%
Hedge Fund
0.03%
Other
99.19%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
25
666.20K
0.82%
-298.05K
2025Q1
28
666.20K
0.82%
-333.59K
2024Q4
27
820.97K
1.18%
-47.15K
2024Q3
26
836.06K
1.21%
+31.78K
2024Q2
28
742.08K
1.07%
+162.52K
2024Q1
32
513.10K
0.74%
-47.53K
2023Q4
30
421.64K
0.61%
-110.65K
2023Q3
32
418.35K
0.60%
-285.66K
2023Q2
33
378.64K
0.55%
-602.57K
2023Q1
34
414.35K
0.60%
-567.89K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
General American Investors Company, Inc.
354.36K
0.44%
--
--
Mar 31, 2025
Wells Fargo Advisors
243.22K
0.3%
-3.55K
-1.44%
Mar 31, 2025
Citadel Advisors LLC
27.22K
0.03%
-42.28K
-60.83%
Mar 31, 2025
Ironwood Investment Management, LLC
25.02K
0.03%
--
--
Mar 31, 2025
VSM Wealth Advisory, LLC
4.00K
0%
+3.00K
+300.00%
Mar 31, 2025
Morgan Stanley & Co. International Plc
3.73K
0%
+2.23K
+149.00%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.88K
0%
--
--
May 31, 2025
Morgan Stanley Smith Barney LLC
1.48K
0%
+250.00
+20.34%
Mar 31, 2025
GAMMA Investing LLC
2.08K
0%
+2.08K
--
Mar 31, 2025
Osaic Holdings, Inc.
1.30K
0%
+1.30K
--
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
